HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
2021 · Infectious Diseases and Therapy · 68 citations
https://doi.org/10.1007/s40121-021-00522-7
L
Lee Evitt
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
214
Citations
6
h-index
6
i10-index
Lee Evitt is an academic researcher from ViiV Healthcare (United Kingdom). The author has contributed to research in topics: HIV/AIDS drug development and treatment & Asthma and respiratory diseases & HIV/AIDS Research and Interventions. The author has an h-index of 6, co-authored 12 publications.
Papers by this author
worksAn indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
2023 · AIDS Research and Therapy · 10 citations
https://doi.org/10.1186/s12981-023-00507-1
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
2024 · AIDS and Behavior · 2 citations
https://doi.org/10.1007/s10461-024-04479-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat